Bridging the Gap: Why the Future of Commercial Pharma Lives Outside the Prescription

Session details:

Patients today face a "diagnostic odyssey" that creates a massive commercial bottleneck and a profound personal burden. Fullspan Health’s study of over 1,450 patients reveals that 55% spend over a year seeking a diagnosis, with nearly 30% waiting over three years. However, a seismic shift is underway as AI is becoming a first point of care with 38% of recently diagnosed patients using AI monthly to navigate their health. This session uses hot off the press patient sentiment to examine the necessity for consumer facing digital health to serve as the core care backbone in even the most complex therapeutic areas, asserting that a Pharma industry-led new commercial model is essential to bridge the gap from symptom onset to ongoing support in 2026 and beyond.